Yang Q, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. World J Clin Cases 2023; 11(31): 7593-7609 [PMID: 38078145 DOI: 10.12998/wjcc.v11.i31.7593]
Corresponding Author of This Article
Qing Yang, MMed, Doctor, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117 Meishan Road, Hefei 230031, Anhui Province, China. cbdcnmyy929@sina.com
Research Domain of This Article
Oncology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2023; 11(31): 7593-7609 Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593
Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer
Qing Yang, Li-Yuan Li
Qing Yang, Li-Yuan Li, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China
Author contributions: Yang Q and Li LY contributed equally to this work; Yang Q and Li LY designed the study; Yang Q contributed to the analysis of the manuscript; Yang Q and Li LY were involved in the data and writing of this article; and all authors have read and approved the final manuscript.
Institutional review board statement: This study adopts network pharmacology and molecular docking simulation methods without requiring hospital ethical approval.
Informed consent statement: This study did not involve human experiments and does not require the signing of an informed consent form.
Conflict-of-interest statement: Yang Q and Li LY Declaration that there is no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing Yang, MMed, Doctor, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117 Meishan Road, Hefei 230031, Anhui Province, China. cbdcnmyy929@sina.com
Received: August 23, 2023 Peer-review started: August 23, 2023 First decision: September 13, 2023 Revised: October 9, 2023 Accepted: October 23, 2023 Article in press: October 23, 2023 Published online: November 6, 2023 Processing time: 74 Days and 23.9 Hours
ARTICLE HIGHLIGHTS
Research background
Lung cancer (LC) is the second highest disease in the world in terms of incidence rate and the main cause of cancer-related deaths.
Research motivation
Liu-Wei-Bu-Qi capsule (LBC) can reduce radiotherapy and chemotherapy-induced side effects such as anorexia and hair loss, and improve the immune response of tumor patients, and improve the quality of life for patients.
Research objectives
The purpose of this study is to investigate the potential targets and signaling pathways of LBC in the treatment of LC.
Research methods
Network pharmacology and molecular docking simulations were used to analyze the relationship among the main components, targets, and signaling pathways of LBC in treatment of LC.
Research results
The analysis results indicate that the main component for treating LC in LBC may be quercetin, which may be used to treat LC by regulating the endothelial growth factor signaling pathway, Toll like receptor signaling pathway, prolactin signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, and HIF-1 signaling pathway. Molecular docking simulations indicate that quercetin has the best affinity for MAPK3, suggesting that quercetin in LBC may play an important role in the treatment of LC.
Research conclusions
The results showed that the active ingredients in LBC can play a crucial role in the treatment of LC by regulating multiple signaling pathways.
Research perspectives
Predicting potential targets and mechanisms for LBC treatment of LC based on network pharmacology and molecular docking.
